Silexion Therapeutics ($SLXN) just filed for a fresh public offering. They’re a clinical-stage biotech developing RNAi therapies for KRAS-driven cancers, with a lead candidate targeting pancreatic can

Their lead asset SIL204 just activated a Phase 2/3 trial site in Tel Aviv, with nods from Israeli and German regulators. Solid progress, but the runway’s been stitched together with small raises—$6M in Sept 2025 and ~$1M from warrant exercises. The risk here is blunt: a 1-for-10 reverse split in May 2026 already flagged the struggle to stay Nasdaq-compliant. Combine that with a brutal biotech IPO market—only 7 completed in H1 2025—and the window is narrow for early-stage names. Bottom line: SLXN is fighting to fund mid-stage oncology assets in a market that’s largely frozen to pre-revenue biotech. The science has momentum, but the capital path remains hand-to-mouth and highly dilutive.

Their lead asset SIL204 just activated a Phase 2/3 trial site in Tel Aviv, with nods from Israeli and German regulators. Solid progress, but the runway’s been stitched together with small raises—$6M in Sept 2025 and ~$1M from warrant exercises.